Services
Clinical Trials
The treatment of alcoholism with opioid antagonists has been shown to be effective in several double-blind, placebo-controlled clinical trials, including the early ones at the University of Pennsylvania (Volpicelli et al., Archives of General Psychiatry 49:876-879, 1992), Yale University (O'Malley et al., Archives of General Psychiatry 49:881-887, 1992; 53:217-224, 1996), and the University of Miami (Mason et al., Alcoholism: Clinical and Experimental Research 18:1162-1167, 1994). There are also plenty of other publications on the subject.
Accepted by government agencies
The Federal Drug Administration of the United States has approved naltrexone for "use within a comprehensive treatment program for alcohol dependence to reduce the risk of relapse, support abstinence and reduce alcohol craving".
It is the first new drug to be approved for alcoholism in 47 years. It has been approved also in Canada, Austria, Israel, France, Italy, Denmark, and Finland, and recognized by the WHO as a "safe and effective treatment for alcohol dependence." Note, however, that laboratory studies suggest naltrexone used incorrectly may be counterproductive.
|
Contact us:
